New drug aimed at folate receptor shows promise for tough endometrial cancer

NCT ID NCT03832361

Recruiting now Disease control Sponsor: Alessandro Santin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called mirvetuximab soravtansine in 50 women with a specific type of endometrial cancer that has come back or won't go away. The drug targets a protein called folate receptor alpha, which is often found on these cancer cells. Researchers want to see if the drug can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirvetuximab soravtansine (IMGN853)
What this could lead to: If successful, this could provide a new treatment option for women with a hard-to-treat form of endometrial cancer that has come back.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinosarcoma clear cell adenocarcinoma endometrial cancer endometrial serous adenocarcinoma endometrium adenocarcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

Smilow Cancer Hospital at Yale New Haven
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.